The data reported in Figure 3 and 4 suggest that strong PAPSS1 inhibition enhances cisplatin activity in four different NSCLC cell lines and these data stress the importance of identifying small molecule inhibitors of PAPSS1 as siRNA therapeutic approaches will likely be difficult to deliver in therapeutically relevant doses to achieve sufficient inhibition of PAPSS1 within a heterogeneous population of tumor cells. This evidence concerns the gene PAPSS1 and neoplasm.